Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis
Bruno Roche, Mylene Sebagh, Maria Laura Canfora, Teresa Antonini, Anne‐Marie Roque‐Afonso, Valerie Delvart, Faouzi Saliba, Jean‐Charles Duclos‐Vallee, Denis Castaing, Didier Samuel – 24 November 2008 – Antiviral therapy after liver transplantation (LT) using interferon (IFN) and ribavirin (RBV) can achieve a sustained virological response (SVR) rate ranging from 20% to 45%. The aims of our study were to assess efficacy and tolerability of therapy, effect on fibrosis progression and the importance of the initial fibrosis stage to outcome.